NurExone Biologic Inc. is delighted to share an incredibly positive preclinical study result related to its investigational drug ExoPTEN. Imaging results confirmed successful regeneration of the spinal cord in rats which had experienced traumatic transection. Moreover, this novel treatment was observed to produce remarkable recovery in motor function in 75% of rats previously paralyzed by spinal cord injuries. This groundbreaking achievement is a truly encouraging sign for those seeking more effective treatments for such debilitating conditions.
During an internal preclinical trial, the company’s ExoPTEN drug yielded highly promising results, with 75% of the rats regaining hind limb reflex, motor function, and sensory control. To further investigate the drug’s effect on the spinal cord, the rats from the study underwent advanced Diffusion Tensor Imaging (DTI), which provided insightful data about the structural integrity of the spinal cord in different rat groups.
NurExone’s ExoPTEN is a revolutionary ExoTherapy for spinal cord injuries that is being developed to reduce tissue microstructural damage. This minimally invasive therapy is administered intranasally, offering neuron regeneration and rewiring of traumatically damaged spinal cords using the company’s proprietary ExoTherapy platform.
Adopting Fractional Anisotropy measurements, ExoPTEN was compared to a control SCI group to examine the treatment’s efficacy. The results revealed that this therapy resulted in higher Fractional Anisotropy values, suggesting reduced tissue microstructural damage in the caudal region and better survival of nerves below the lesion site. An additional experiment was also conducted to provide reference values for the healthy rat FA. With ExoPTEN, we can strive towards better quality of life for those affected by spinal cord injuries.
We are thrilled to announce the success of our ExoPTEN product in uncovering reinnervation as a result of the study. Our non-invasive approach has been proven to bring remarkable functional recovery – an invaluable outcome for the millions facing this condition worldwide. With this breakthrough, we are motivated to make further progress in our research and clinical trials to bring our product to the masses.
Figure Legend:
MRI and DTI scans were used to assess the structural integrity of the spinal cord in control-treated SCI animals, ExoPTEN-treated SCI animals, and intact rats. While the caudal nerve tracts of control-treated SCI animals were completely severed, causing atrophy of the caudal spinal cord, ExoPTEN was able to restore nourishment and promote reinnervation of the caudal spinal cord.
A breakthrough comparison between ExoPTEN-treated rats and a control SCI group reveals a remarkable recovery of the tissue integrity in the former. The highly reliable fractional anisotropy (FA) recordings of caudal to the injury site validate this. In the ExoPTEN-treated rats, the FA values are tantalizingly close to the standard range of healthy rats. This promises a vast potential for intranasal ExoPTEN treatment in spinal cord injury cases. Additionally, this DTI tractography evidence demonstrates the re-innervation and nourishment of the caudal spinal cords.
About NurExone Biologic Inc.
NurExone Biologic Inc., listed on the TSX Venture Exchange, is unlocking a world of possibilities for those suffering from traumatic spinal cord injuries. Through the pioneering concept of ExoTherapy, tested on animals at the Technion, Israel Institute of Technology, NurExone is safely delivering a non-invasive treatment to patients. The Company holds an exclusive worldwide license from the Technion and Tel Aviv University to develop and commercialize this revolutionary technology that could revolutionize healthcare worldwide.